133115-37-4

Upstream product

• 2680-03-7 N,N-Dimethylacrylamide 
• 64923-12-2 tert-butyl benzylideneaminoacetate 

Downstream Products

• 138646-92-1 tert-butyl (RS)-2-anilino-2-(4-methoxyphenyl)acetate 
• 138646-69-2 tert-butyl (RS)-2-(3,4-dichlorophenyl)-2-{2-[3-(3-methylphenyl)ureido]-N-phenylacetamido}acetate 
• 138646-74-9 tert-butyl (RS)-2-(3-bromophenyl)-2-{2-[3-(3-methylphenyl)ureido]-N-phenylacetamido}acetate 
• 138646-76-1 ethyl (RS)-3-{2-[3-(3-methylphenyl)ureido]-N-phenylacetamido}-3-phenylpropionate 
• 138561-70-3 tert-butyl (RS)-2-{2-[3-(3-methylphenyl)ureido]-N-phenylacetamido}-2-[(1-pyrrolidinyl)carbonyl]acetate 
• 138561-71-4 tert-butyl (RS)-2-{2-[3-(3-methylphenyl)ureido]-N-phenylacetamido}-2-phenylcarbamoylacetate 
• 138562-00-2 ethyl (RS)-2-{2-[3-(3-methylphenyl)ureido]-N-phenylacetamido}-2-phenylcarbamoylacetate 
• 138562-01-3 tert-butyl (RS)-2-[(3,3-dimethyl-1-piperidino)carbonyl]-2-{2-[3-(3-methylphenyl)ureido]-N-phenylacetamido}acetate 

Relevant academic research and scientific papers

N-acylpyrrolidines and medicaments for the treatment or prevention of disorders linked to CKK and to gastrin

The present invention relates to derivatives of formula: STR1 to their salts, to their preparation and to the medicaments containing them.

N-phenyl-N-acetamidoglycinamides, their preparation and medicaments containing them

Compounds of formula: STR1 in which R1 represents a hydrogen atom or an alkyl, alkoxycarbonyl or an unsubstituted or substituted phenyl radical, R2 represents a hydrogen atom or an unsubstituted or substituted alkyl radical, R3 represents an alkyl, phenylalkyl, indanyl, cycloalkylalkyl or an unsubstituted or substituted phenyl radical, or R2 and R3 form a heterocycle together with the nitrogen atom to which they are attached, and R4 represents an unsubstituted or substituted phenyl radical, a naphthyl, indolyl or quinolyl radical or a phenylamino radical in which the phenyl ring is unsubstituted or substituted, their preparation and medicaments containing them.

N-phenylglycinamide CCK antagonists and pharmaceutical compositions containing them

Compounds of formula: STR1 in which R1 represents a hydrogen atom, an alkyl or alkoxycarbonyl radical or a phenyl radical, optionally substituted, R2 represents an alkoxy, optionally substituted cycloalkyloxy, cycloalkylalkyloxy, phenylalkyloxy, polyfluoroalkyloxy or cinnamyloxy radical or a radical --NR5 R6, R3 represents a phenylamino radical in which the phenyl ring is optionally substituted, an optionally substituted phenyl radical or a naphthyl, indolyl or quinolyl radical, R4 represents a substituted phenyl radical, R5 and R6, which may be identical or different, represent a hydrogen atom or an alkyl, optionally substituted phenyl, indanyl, cycloalkylalkyl, cycloalkyl or phenylalkyl radical, or alternatively R5 and R6, together with the nitrogen atom to which they are attached, form a heterocycle, their preparation and medicinal products containing them.

N-phenyl-n-alkoxycarbonylalkyl glycinamides, their preparation and the medicaments containing them

This invention relates to compounds of formula: STR1 in which R1 represents a hydrogen atom or an alkyl or alkoxycarbonyl radical or an unsubstituted or substituted phenyl radical, R2 represents an alkyl (1-8 C) or polyfluoroalkyl ra